- NCIt
- C2896
Loading cancer entity…
Loading cancer entity…
Clinical trials
89 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT00975819 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | completed | Phase 2 | 61 | Denise Martin AdamsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05799157 |
| Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts |
| completed |
| Phase 2 |
| 153 |
| Veradermics, Inc.INDUSTRY |
| 1 |
| May 8, 2025 |
| clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05877313 | Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | completed | Phase 2 | 20 | Sanotize Research and Development corp.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | completed | Phase 2 | 157 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | completed | Phase 2 | 159 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT03090971 | Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | completed | Phase 2 | 7 | Fundação Educacional Serra dos ÓrgãosOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02483455 | ALC-919 For The Treatment Of Common Warts | completed | Phase 2 | 21 | Veloce BioPharma LLCINDUSTRY | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01214564 | Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis | completed | Phase 2 | 24 | PeplinINDUSTRY | 1 | Jan 25, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2026source: clinicaltrials